当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea.

Mebeverine decreases mass movements and stool frequency in lactulose-induced diarrhoea.

Abstract：

BACKGROUND:In spite of its frequent use in the treatment of irritable bowel disease little is known about mebeverine's mode of action in man. AIM:To examine mebeverine's effect on transit though the gut during lactulose-induced diarrhoea. METHODS:Nine healthy volunteers undertook a two-way randomized crossover study. Diarrhoea was induced using lactulose pre-treatment (20 m t.d.s., 4 days) and subjects received either mebeverine (135 mg t.d.s.) or no treatment. Transit of two enteric-coated capsules containing radiolabelled 8.4 mm tablets and 180-250 microM ion exchange resin were followed using gamma scintigraphy. Stool frequency and symptoms were assessed by diary cards. RESULTS:Mebeverine reduced mean daily stool frequency associated with lactulose ingestion from a median of 2.25 (interquartile range (IQR) 1.75-2.75) to 1.5 (IQR 1.25-2.25) movements. Mebeverine significantly reduced the number of mass movements observed in the colon during the 11 h of the study from 2 (2-2) to 1 (1-2), and the number of retrograde movements from 1 (0-2) to 0 (0-0) (P < 0.05). Mebeverine did not significantly alter the gastric emptying rate of the intact capsule (2.9 (1.9-3.2) to 2.8 (2.6-4.0) h) however it induced a small but significant acceleration in small intestinal transit of the capsule (1.6 (0.8-2.0) h to 1.0 (0.52-1.32) h, P=0.02). CONCLUSION:Mebeverine reduces the diarrhoeal effect of lactulose by decreasing the mass movements induced in the ascending colon. This effect may contribute to its clinical effect in irritable bowel syndrome.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Washington N,Ridley P,Thomas C,Spiller RC,Watts PJ,Wilson CG

doi

10.1046/j.1365-2036.1998.00340.x

subject

Has Abstract

pub_date

1998-06-01 00:00:00

pages

583-8

issue

6

eissn

0269-2813

issn

1365-2036

journal_volume

12

pub_type

临床试验,杂志文章,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice.

    abstract：BACKGROUND:Malnutrition and jaundice are independent prognostic factors in cirrhosis. AIM:To assess the impact of enteral nutrition on the survival of alcoholic cirrhotic patients with jaundice but without acute alcoholic hepatitis. METHODS:The study was a multicentre prospective randomised controlled trial comparing...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2012.05075.x

    authors： Dupont B,Dao T,Joubert C,Dupont-Lucas C,Gloro R,Nguyen-Khac E,Beaujard E,Mathurin P,Vastel E,Musikas M,Ollivier I,Piquet MA

    更新日期：2012-05-01 00:00:00

  • Personal view: cost and benefit of medical rituals in gastroenterology.

    abstract：BACKGROUND:Unable to resolve a medical problem, gastroenterologists occasionally choose an ineffectual intervention instead. The elusive path to effectual management becomes substituted with an ineffectual but readily available medical ritual. The term 'ritual' refers to the utilization of an ineffectual intervention w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.02252.x

    authors： Sonnenberg A

    更新日期：2004-11-01 00:00:00

  • Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.

    abstract：BACKGROUND:Intravenous esomeprazole may be beneficial for patients who cannot take oral medications. AIM:To compare intravenous esomeprazole with oral esomeprazole for effects on maximal acid output during pentagastrin stimulation in patients with gastro-oesophageal reflux disease symptoms. METHODS:In four separate o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02659.x

    authors： Metz DC,Miner PB,Heuman DM,Chen Y,Sostek M

    更新日期：2005-11-01 00:00:00

  • Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.

    abstract：BACKGROUND:Orlistat reduces energy uptake by the impairment of fat digestion and some evidence indicates it also lowers plasma cholesterol. AIM:To examine total, low-density lipoprotein- and high-density lipoprotein cholesterol during a weight reducing regimen, and assess the effect of orlistat in lowering cholesterol...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2004.01966.x

    authors： Erdmann J,Lippl F,Klose G,Schusdziarra V

    更新日期：2004-06-01 00:00:00

  • Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.

    abstract：BACKGROUND:ONO-2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress-induced defecation and visceral hyperalgesia in rat models. AIM:To evaluate the efficacy and safety of ONO-2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof-of-concept study. ME...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/apt.13839

    authors： Whitehead WE,Duffy K,Sharpe J,Nabata T,Bruce M

    更新日期：2017-01-01 00:00:00

  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract：BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12202

    authors： Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期：2013-03-01 00:00:00

  • Adverse reactions to sulphasalazine and 5-amino salicylic acid in the same patient.

    abstract：:We report a patient who developed sulphasalazine-related hepatitis with a subsequent adverse reaction to rectal 5-amino salicylic acid, in the form of pain and fever without associated liver dysfunction, suggesting reactions to both components of sulphasalazine. Included is a review of the literature. Caution should b...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1987.tb00619.x

    authors： Burke DA,Manning AP,Williamson JM,Axon AT

    更新日期：1987-06-01 00:00:00

  • Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance.

    abstract：BACKGROUND:The seroclearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) is considered to be associated with favourable clinical outcomes. AIMS:This meta-analysis was performed to establish the proportion of HBsAg loss rates among CHB patients who received combination treatment ba...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.14629

    authors： Qiu K,Liu B,Li SY,Li H,Chen ZW,Luo AR,Peng ML,Ren H,Hu P

    更新日期：2018-05-01 00:00:00

  • High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.

    abstract：BACKGROUND:In average-risk patients, the new anti-platelet agent, clopidogrel, causes less upper gastrointestinal adverse events than aspirin. However, there are no safety data on the use of clopidogrel in high-risk patients. AIM:To evaluate the safety of clopidogrel in patients with peptic ulcer disease in a retrospe...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01693.x

    authors： Ng FH,Wong SY,Chang CM,Chen WH,Kng C,Lanas AI,Wong BC

    更新日期：2003-08-15 00:00:00

  • Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages.

    abstract：BACKGROUND:Obesity is associated with non-alcoholic fatty liver disease (NAFLD), and the patatin-like phospholipase 3 (PNPLA3) rs738409 (Ile148Met, C>G) gene polymorphism is one of the most important genetic determinants of NAFLD. Carriers have been reported to better respond to lifestyle modification. AIM:To investig...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13232

    authors： Mangge H,Baumgartner BG,Zelzer S,Prüller F,Schnedl WJ,Reininghaus EZ,Haybaeck J,Lackner C,Stauber R,Aigner E,Weghuber D

    更新日期：2015-07-01 00:00:00

  • Use of acid-suppressive therapy before anti-reflux surgery in 2922 patients: a nationwide register-based study in Denmark.

    abstract：BACKGROUND:Guidelines recommend that patients with gastro-oesophageal reflux disease are adequately treated with acid-suppressive therapy before undergoing anti-reflux surgery. Little is known of the use of acid-suppressive drugs before anti-reflux surgery. AIM:To determine the use of proton pump inhibitors and H2 -re...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13230

    authors： Lødrup A,Pottegård A,Hallas J,Bytzer P

    更新日期：2015-07-01 00:00:00

  • Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

    abstract：BACKGROUND:Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/apt.14197

    authors： Mangia A,Sarli R,Gamberini R,Piga A,Cenderello G,Piazzolla V,Santoro R,Caruso V,Quarta A,Ganga R,Copetti M,Forni G

    更新日期：2017-08-01 00:00:00

  • Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

    abstract：BACKGROUND:Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients. AIM:To analyse the efficacy and tolerability of antiviral interferon/ribavirin therapy in patients with...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03779.x

    authors： Scherzer TM,Staufer K,Novacek G,Steindl-Munda P,Schumacher S,Hofer H,Ferenci P,Vogelsang H

    更新日期：2008-09-15 00:00:00

  • Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients.

    abstract：BACKGROUND:Recently, the therapeutic landscape with regard to anti-HCV therapy has changed dramatically. The new directly acting anti-virals (DAAs) have demonstrated improved sustained virological response (SVR) compared with pegylated-interferon and ribavirin. AIM:To examine and present the latest data with regard to...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12260

    authors： Joshi D,Carey I,Agarwal K

    更新日期：2013-04-01 00:00:00

  • Review article: the impact of diet on ileoanal pouch function and on the pathogenesis of pouchitis.

    abstract：BACKGROUND:There is expanding interest in the role that diet plays in ileoanal pouch function and in the pathogenesis of pouchitis. AIMS:To present a narrative review of published literature regarding the relationship of diet with pouch function and the pathogenesis of pouchitis, and to provide potentially beneficial ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.16085

    authors： Ardalan ZS,Yao CK,Sparrow MP,Gibson PR

    更新日期：2020-10-01 00:00:00

  • Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis.

    abstract：BACKGROUND:Pregabalin has a broad spectrum of analgesic and antihyperalgesic activity in both basic and clinical studies. However, its mechanisms and sites of action have yet to be determined in humans. AIMS:To assess the antinociceptive effect of pregabalin on experimental gut pain in patients with visceral hyperalge...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2011.04802.x

    authors： Olesen SS,Graversen C,Olesen AE,Frøkjaer JB,Wilder-Smith O,van Goor H,Valeriani M,Drewes AM

    更新日期：2011-10-01 00:00:00

  • Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.

    abstract：BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15370

    authors： Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

    更新日期：2019-08-01 00:00:00

  • The impact of gastrointestinal symptoms on health status in patients with cardiovascular disease.

    abstract：BACKGROUND:Drugs for the management of cardiovascular disease may provoke gastrointestinal discomfort and complications. AIM:To evaluate whether upper gastrointestinal symptoms affect the health status of patients with cardiovascular disease. METHODS:Two weeks after discharge, 958 consecutive patients, who had been a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01542.x

    authors： Laheij RJ,Van Rossum LG,Krabbe PF,Jansen JB,Verheugt FW

    更新日期：2003-04-01 00:00:00

  • Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis.

    abstract：BACKGROUND:Cardiac dysfunction is frequently observed in patients with cirrhosis. There remains a paucity of data from routine clinical practice regarding the role of echocardiography in the pre-assessment of transjugular intrahepatic portosystemic stent-shunt. AIM:Our study aimed to investigate if echocardiography pa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15164

    authors： Armstrong MJ,Gohar F,Dhaliwal A,Nightingale P,Baker G,Greaves D,Mangat K,Zia Z,Karkhanis S,Olliff S,Mehrzad H,Steeds RP,Tripathi D

    更新日期：2019-03-01 00:00:00

  • Systematic review: has disease outcome in Crohn's disease changed during the last four decades?

    abstract：BACKGROUND:Disease outcome in Crohn's disease might have changed during the last four decades. Disease outcome measurement in Crohn's disease has methodological difficulties because of patient selection and lack of proper definition of diagnostic and outcome measurement criteria. AIM:To assess possible changes in dise...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02123.x

    authors： Wolters FL,Russel MG,Stockbrügger RW

    更新日期：2004-09-01 00:00:00

  • Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study.

    abstract：BACKGROUND:In developed countries, hepatitis E is a porcine zoonosis caused by hepatitis E virus (HEV) genotype 3. In developing countries, hepatitis E is mainly caused by genotype 1, and causes increased mortality in patients with pre-existing chronic liver disease (CLD). AIM:To determine the role of HEV in patients ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13309

    authors： Blasco-Perrin H,Madden RG,Stanley A,Crossan C,Hunter JG,Vine L,Lane K,Devooght-Johnson N,Mclaughlin C,Petrik J,Stableforth B,Hussaini H,Phillips M,Mansuy JM,Forrest E,Izopet J,Blatchford O,Scobie L,Peron JM,Dalton H

    更新日期：2015-09-01 00:00:00

  • The coeliac stomach: gastritis in patients with coeliac disease.

    abstract：BACKGROUND:Lymphocytic gastritis (LG) is an uncommon entity with varying symptoms and endoscopic appearances. This condition, as well as two forms of H. pylori-negative gastritis [chronic active gastritis (CAG) and chronic inactive gastritis (CIG)], appears to be more common in patients with coeliac disease (CD) based ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13249

    authors： Lebwohl B,Green PH,Genta RM

    更新日期：2015-07-01 00:00:00

  • The use of ciclosporin in paediatric inflammatory bowel disease: an Italian experience.

    abstract：AIM:To asses the efficacy and safety of ciclosporin in a paediatric population with inflammatory bowel disease. PATIENTS AND METHODS:Twenty-three Italian children treated with ciclosporin were studied retrospectively. The indications for treatment were severe unresponsive colitis, chronic active colitis or severe fist...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1046/j.1365-2036.2002.01308.x

    authors： Barabino A,Torrente F,Castellano E,Gandullia P,Calvi A,Cucchiara S,De GL,Fontana M,Lionetti P,De Giacomo C,Gissi A

    更新日期：2002-08-01 00:00:00

  • Determinants of diagnostic delay in autoimmune atrophic gastritis.

    abstract：BACKGROUND:Autoimmune atrophic gastritis (AAG) is characterised by a wide clinical spectrum that could delay its diagnosis. AIMS:To quantify the diagnostic delay in patients suffering from AAG and to explore possible risk factors for longer diagnostic delay. METHODS:Consecutive patients with AAG evaluated at our gast...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15317

    authors： Lenti MV,Miceli E,Cococcia S,Klersy C,Staiani M,Guglielmi F,Giuffrida P,Vanoli A,Luinetti O,De Grazia F,Di Stefano M,Corazza GR,Di Sabatino A

    更新日期：2019-07-01 00:00:00

  • A comparison between enprostil and ranitidine in the management of gastric ulceration.

    abstract：:In a randomly allocated, double-blind, endoscopically controlled study, 98 patients with gastric ulcers were treated with either (a synthetic prostaglandin of E2-like structure) enprostil 70 micrograms b.d. or 150 mg ranitidine b.d. The healing rates at 4, 8 and 12 weeks were enprostil 57, 91 and 94% and for ranitidin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1990.tb00511.x

    authors： Morgan AG,Pacsoo C,Taylor P,McAdam WA

    更新日期：1990-12-01 00:00:00

  • Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.

    abstract：BACKGROUND:Hispanic-Americans are a rapidly growing population in the United States, yet gastro-oesophageal reflux disease (GERD) is not well studied in this population. AIM:To compare the efficacy of esomeprazole, lansoprazole and pantoprazole in suppressing gastric acid, including the area of the 'acid pocket,' in H...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2010.04335.x

    authors： Morgan D,Pandolfino J,Katz PO,Goldstein JL,Barker PN,Illueca M

    更新日期：2010-07-01 00:00:00

  • Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials.

    abstract：BACKGROUND:Variation in the characteristics of irritable bowel syndrome patients recruited for clinical trials from different sources could affect their response and the generalizability of trial results. AIM:To describe and compare the characteristics of three different groups of irritable bowel syndrome patients rec...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2001.01010.x

    authors： Longstreth GF,Hawkey CJ,Mayer EA,Jones RH,Naesdal J,Wilson IK,Peacock RA,Wiklund IK

    更新日期：2001-07-01 00:00:00

  • Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis.

    abstract：BACKGROUND:No definitive method for quantitative evaluation of hepatic function has as yet been established. AIM:To investigate whether the (13)C-phenylalanine breath test would be useful for the evaluation of hepatic function in patients with liver cirrhosis and acute hepatitis. METHODS:L-[1-(13)C]-phenylalanine was...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02409.x

    authors： Koeda N,Iwai M,Kato A,Suzuki K

    更新日期：2005-04-01 00:00:00

  • Systematic review: microscopic colitis.

    abstract：BACKGROUND:Collagenous and lymphocytic colitis are fairly common causes of chronic non-bloody diarrhoea, especially in elderly female. AIM:To present a systematic review of microscopic colitis. METHODS:A PubMed search using the MeSH terms microscopic colitis, collagenous colitis, lymphocytic colitis and chronic diarr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02913.x

    authors： Nyhlin N,Bohr J,Eriksson S,Tysk C

    更新日期：2006-06-01 00:00:00

  • Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.

    abstract：BACKGROUND:There are limited data concerning infliximab drug monitoring during de-escalation of the treatment of inflammatory bowel disease (IBD). AIM:To define the rate and the predictors of relapse following infliximab de-escalation in IBD patients in remission. METHODS:All IBD patients at a single referral centre ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15046

    authors： Lucidarme C,Petitcollin A,Brochard C,Siproudhis L,Dewitte M,Landemaine A,Bellissant E,Bouguen G

    更新日期：2019-01-01 00:00:00